Kenneth S. Koblan PhD

Kenneth S. Koblan Ph.D. is Head of Global Translational Medicine & Early Development (TMED) and Head of Discovery Sciences at Sunovion, which is focused on the innovative application of science and medicine to help people with serious psychiatric, neurological, and respiratory conditions. Dr. Koblan oversees a team of clinical research scientists with expertise in imaging, modeling and simulation, clinical pharmacology, and bioinformatics applied to the development of new medical therapies. Sunovion is heavily invested in meeting unmet medical needs, applying innovative AI and machine learning approaches in the area of neurobiology, and working in research collaborations worldwide.

Dr. Koblan has 28 years of experience in the biopharmaceutical industry. Prior to joining Sunovion in 2011, he held scientific leadership roles at Merck Research Laboratories and Alnylam Pharmaceuticals Inc. Dr. Koblan has contributed to the registration of medicines in a broad range of therapeutic areas including oncology (GARDASIL), diabetes (JANUVIA), neurology (BELSOMRA), and the first-ever RNA interference drug (ONPATTRO).

Dr. Koblan has authored over 100 peer-reviewed scholarly articles and holds numerous patents. He was selected by harmaVOICE in 2017 as one of the "100 Most Inspiring People" in the pharmaceutical industry, recognized for his innovation and collaboration in advancing central nervous system (CNS) drug development.

Dr. Koblan received his Ph.D. in Biochemistry from Johns Hopkins University and his Bachelor of Science degree in Biology from the Massachusetts Institute of Technology (MIT).